Prevention of tissue ischemia and related methods
Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.
1. A method of increasing tissue perfusion in a subject, comprising:
selecting a subject in need of increased tissue perfusion; and
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a humanized antibody to thrombospondin-1 (TSP1), wherein the humanized antibody is a humanized version of antibody A6.1 or a humanized version of antibody C6.7,
thereby increasing tissue perfusion in the subject.
2. The method of claim 1 , wherein the subject has or is at risk of developing at least one disease or condition selected from the group consisting of: ischemia/reperfusion injury, myocardial infarction, myocardial ischemia, stroke, cerebral ischemia, sickle cell anemia, and pulmonary hypertension.
3. The method of claim 1 , wherein the subject is a human of about 65 or more years of age.
4. The method of claim 1 , further comprising administering a therapeutically effective amount of a nitric oxide donor or precursor, nitrovasodilator, activator of soluble guanylyl cyclase, or cGMP phosphodiesterase inhibitor to the subject.
5. The method of claim 1 , wherein the subject has or is at risk of developing at least one disease or condition selected from the group consisting of: hypertension, atherosclerosis, vasculopathy, ischemia secondary to diabetes, and peripheral vascular disease.
6. The method of claim 1 , wherein the need for increased tissue perfusion arises because the subject has had, is having, or will have a surgery selected from the group consisting of: integument surgery, soft tissue surgery, composite tissue surgery, skin graft surgery, and surgery for reattachment of severed body parts.
7. The method of claim 1 , wherein the need for increased tissue perfusion arises because the subject has had, is having, or will have organ transplant surgery.
8. A method comprising:
selecting a subject to be subjected to ischemia; and
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a humanized antibody to thrombospondin-1 (TSP1), wherein the humanized antibody is a humanized version of antibody A6.1 or a humanized version of antibody C6.7,
thereby reducing direct ischemic injury and/or ischemia/reperfusion injury in the subject when the subject is subjected to ischemia.
9. The method of claim 8 , wherein the ischemia arises because the subject will have or is having a surgery selected from the group consisting of: integument surgery, soft tissue surgery, composite tissue surgery, skin graft surgery, and surgery for reattachment of severed body parts.
10. The method of claim 9 , wherein the skin graft is an autograft.
11. The method of claim 8 , wherein the ischemia arises because the subject will have or is having organ transplant surgery.
12. The method of claim 8 , wherein the subject is a human of about 65 or more years of age.
13. The method of claim 8 , further comprising administering a therapeutically effective amount of a nitric oxide donor or precursor, nitrovasodilator, activator of soluble guanylyl cyclase, or cGMP phosphodiesterase inhibitor to the subject.
14. A method of treating a subject, comprising:
selecting a subject that has or is at risk of direct ischemic injury or ischemia/reperfusion injury; and
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a humanized antibody to thrombospondin-1 (TSP1), wherein the humanized antibody is a humanized version of antibody A6.1 or a humanized version of antibody C6.7,
thereby treating the direct ischemic injury and/or ischemia/reperfusion injury in the subject.
15. The method of claim 14 , wherein the subject has or is at risk of a disease or condition selected from the group consisting of: myocardial infarction, myocardial ischemia, stroke, cerebral ischemia, sickle cell anemia, and pulmonary hypertension.
16. The method of claim 14 , wherein the subject has or is at risk of a disease or condition selected from the group consisting of: hypertension, atherosclerosis, vasculopathy, ischemia secondary to diabetes, and peripheral vascular disease.
17. The method of claim 14 , wherein the pharmaceutical composition is administered before, during, or after the subject undergoes surgery.
18. The method of claim 17 , wherein the surgery is selected from the group consisting of: integument surgery, soft tissue surgery, composite tissue surgery, skin graft surgery and surgery for reattachment of severed body parts.
19. The method of claim 17 , wherein the surgery is organ transplant surgery.
20. The method of claim 14 , wherein the subject is a human of about 65 or more years of age.
21. The method of claim 14 , further comprising administering a therapeutically effective amount of a nitric oxide donor or precursor, nitrovasodilator, activator of soluble guanylyl cyclase, or cGMP phosphodiesterase inhibitor to the subject.
22. A method, comprising:
selecting a donor organ; and
administering to the donor organ, prior to its transplantation into the recipient, a therapeutically effective amount of a pharmaceutical composition comprising a humanized antibody to thrombospondin-1 (TSP1), wherein the humanized antibody is a humanized version of antibody A6.1 or a humanized version of antibody C6.7,
thereby reducing direct ischemic injury and/or ischemia/reperfusion injury in the donor organ.
23. The method of claim 22 , further comprising administering a therapeutically effective amount of a nitric oxide donor or precursor, nitrovasodilator, activator of soluble guanylyl cyclase, or cGMP phosphodiesterase inhibitor to the subject.
24. The method of claim 1 , wherein the increased tissue perfusion occurs within 24 hours of administration of the composition.
25. The method of claim 14 , wherein treating the direct ischemic injury and/or ischemia reperfusion injury occurs within 24 hours of administration of the composition.